Novel antibiotics combination therapy against MRSA strains

Abstract

Methicillin-resistant Staphylococci aureus (MRSA) is one of the most serious infection which resist most β-lactam antibiotics. MRSA infections are thus difficult to treat, with limited medication options available, while the development of new antibiotics is high-risk, expensive, and long-term endeavour, antibiotics combination therapy become a promising strategy to overcome resistance. Previous high throughput screening by our group identified rifaximin as an agent capable augmenting amoxicillin against MRSA strain JE2. This study aims to validate the result of the screening by developing a novel antibiotics combination to treat different MRSA strains